Search Results

< Back to the upcoming events page ABOUT The Neuroendocrine Cancer Foundation is hosting an in-person NET Educational Event for patients and caregivers in Tucson, Arizona on Saturday, March 29th, from 1:30-6:00 PM. Hear presentations from 8 NET experts. Listen to patient stories. Learn about the latest in surgery, liver-directed therapy, systemic therapy, PRRT, and clinical trials. Ask questions during the extended live question and answer session. Find out how you can spread awareness about neuroendocrine cancer. Network with other patients and caregivers in the post-event reception. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Special thanks to our host, Dr. Junaid Arshad, University of Arizona Cancer Center (UACC). This event will not be broadcast. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> THANKS TO OUR SUPPORTERS AGENDA Time Topic Speaker 1:30 - 2 PM Check-in 2 - 2:10 PM Welcome & Introductions Neuroendocrine Cancer Foundation Team 2:10 - 2:15 PM Patient Story Kimberly, NET Patient 2:15 - 2:30 PM NETs 101: NET Terms & Concepts You Need to Know Bassam Sonbol, MD, Medical Oncologist, Mayo Clinic Phoenix 2:30 - 2:45 PM Surgery for NETs: To Cut or Not to Cut? Gagandeep Singh, MD, Surgical Oncologist, City of Hope Phoenix 2:45 - 3 PM Liver-Directed Therapy: Killing Liver Tumors Without a Big Scar Gregory Woodhead, MD, PhD, Interventional Radiologist, University of Arizona Cancer Center 3 - 3:15 PM Systemic Therapy for NETs: Treatment Options for Metastatic Tumors Heloisa Soares, MD, PhD, Medical Oncologist, Huntsman Cancer Institute 3:15 - 3:30 PM PRRT: Current & New Trends Holly Thompson, MD, MPH, Nuclear Medicine, University of Arizona Cancer Center 3:30 - 3:45 PM Break 3:45 - 3:50 PM Nursing Perspective on the Management of NETs Linda Moe, RN, University of Arizona Cancer Center 3:50 - 4:05 PM Clinical Trials: The Latest & Greatest Pamela Kunz, MD, Medical Oncologist, Yale Cancer Center 4:05 - 5 PM Q&A with Expert Panel All Faculty - Moderated by Dr. Junaid Arshad, Medical Oncologist, University of Arizona Cancer Center & Lisa Yen, LACNETS 5 - 6 PM Networking Reception ABOUT OUR SPEAKERS Dr. Junaid Arshad Medical Oncologist, University of Arizona Cancer Center (UACC) Host/Moderator/Speaker Dr. Junaid Arshad is an Assistant Professor of Medicine and our new faculty member of GI Medical Oncology. He received his medical degree from King Edward Medical University, Lahore, Pakistan. He completed his Internal Medicine Residency at St. Mary's Hospital, Waterbury, CT. He has joined the Cancer Center after his Hematology and Medical Oncology Fellowship from University of Miami, FL. Dr. Arshad is a Clinical and Translational Scientist with a focus on developing novel therapeutics for several areas of Upper GI Oncology. Dr. Arshad's Clinical and Research focus targets mainly the Upper GI Oncology including Gastrointestinal Stromal Tumors, Gastric Cancers, Esophageal Cancers and Neuroendocrine Tumors. He is a part of several clinical trials and has contributed to several peer reviewed publications. His prior research focuses on the use of biomarkers such as circulating tumor DNA (ctDNA) in the diagnosis, treatment and surveillance of Gastrointestinal Stromal Tumors. He has expanded his areas of research interest to include other disease modalities such as Neuroendocrine Cancers. Dr. Pamela Kunz Medical Oncologist, Yale Cancer Center Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including past President of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. Dr. Kunz was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021. Dr. Kunz was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity and received the 2024 'Distinguished Mentor Award' by the North American Neuroendocrine Tumor Society. X @PamelaKunzMD Linda Moe, RN Registered Nurse, University of Arizona Cancer Center (UACC) I have been an oncology nurse for 34 years, working in both inpatient and outpatient settings. My experiences range from bedside nursing, ambulatory care, ICU care, charge nurse, nurse manager, nurse navigator and RN coordinator. Currently, I am working as Dr. Arshad’s RN coordinator. I have been working specifically with GI cancers for the past seven years. I spearheaded and achieved NAPRC accreditation status at the University of Arizona Cancer Center. I have specialized in Bone Marrow Transplant, pain management, palliative care, wound care and end-of-life care. I hold a bachelor’s degree in nursing and a bachelor’s degree in naturopathy with an emphasis on wellness and cancer prevention. I am a Reiki Master with over 20 years of Reiki experience. I was selected as a “Fabulous 50” nurse in 2020 and successfully passed a law establishing “National Fatigue Awareness Day” in the state of Arkansas. Dr. Gagandeep Singh Surgical Oncologist, City of Hope Phoenix Internationally renowned liver and pancreas surgeon Gagandeep “Gaugs” Singh, M.D., F.A.C.S., is Chief of Surgical Oncology and Director of Surgical Services at City of Hope® Cancer Center Phoenix. A seasoned health care leader with more than 20 years’ experience building outstanding surgical teams, Dr. Singh is excited to return to Phoenix – where he completed part of his medical training – and to City of Hope, where he spent a decade as the chief of City of Hope Duarte’s surgical oncology program. In the clinic, Dr. Singh takes a thoughtful yet forceful approach to treating cancers of the liver, pancreas and gastrointestinal systems. As a health care leader, he is passionate about empowering teams to achieve their fullest potential. He has been recognized with numerous awards and leadership positions. After beginning his faculty academic career at the Keck School of Medicine at the University of Southern California in Los Angeles, Dr. Singh was appointed director of the Liver and Pancreas Center at the John Wayne Cancer Institute in Santa Monica, California, where he also served as chair of the Cancer Committee. At City of Hope Duarte, Dr. Singh spearheaded the liver and pancreatic cancer programs and led the Division of Surgical Oncology to national recognition. He has been included on multiple lists of “America’s Top Surgeons,” “Best Doctors of America,” “Super Doctors” and “Top Doctors of America.” Dr. Singh earned his medical degree from the Mahatma Gandhi Institute of Medical Sciences in India, before training at multiple internationally renowned cancer centers, including Tata Memorial Hospital and Cancer Center in Bombay, René Descartes University in Paris and the Royal Liverpool University Hospital in the United Kingdom, as well as the Marion Bessin Liver Center at the Albert Einstein College of Medicine in New York, Maricopa Medical Center in Phoenix and the University of Iowa. A board-certified surgeon, diplomate of the American Board of Surgery and fellow of the American College of Surgeons, Dr. Singh is an internationally recognized expert in his field and a member of the National Comprehensive Cancer Network for Hepatobiliary Cancers, the group that sets the guidelines for the standard of care for hepatobiliary cancers. As a researcher, Dr. Singh has written on topics such as complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions with difficult pancreatic surgery for pancreatic cancer and advanced robotic surgery. His work on robotic surgery has been presented at the Society of Surgical Oncology, America’s Hepato-Pancreato-Biliary Association, the Society of Laparoscopic & Robotic Surgeons and other national meetings. An innovator at heart, he is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborated with engineers from the California Institute of Technology and Harvey Mudd College and has several invention disclosures and patents to his name. Dr. Singh’s translational research includes projects with molecular biologists, X-ray crystallographers, structural chemists and super-resolution scientists across the City of Hope national system . Dr. Heloisa Soares Medical Oncologist, Huntsman Cancer Institute Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79 Dr. Bassam Sonbol Medical Oncologist, Mayo Clinic Phoenix Mohamad Bassam Sonbol, M.D., is an Oncologist, with special interest in neuroendocrine tumors and gastrointestinal malignancies. In addition to his clinical activities, Dr. Sonbol is active in research that focuses on investigating novel treatments including targeted therapies, immunotherapy, and other agents that could potentially help patients with neuroendocrine and gastrointestinal cancers. Dr. Sonbol focuses on the holistic treatment for cancer patients taking into consideration their medical and social aspects that have been affected by their cancer diagnosis. Dr. Holly Thompson Nuclear Medicine & Theranostics, University of Arizona Cancer Center (UACC) My passion for medicine is defined by a tenacious desire to diagnose and treat diseases that cause human suffering. Profoundly inspired by the study of cancer, I pursued research into its biology first working at the Fred Hutchinson Cancer Center and then related innovative imaging technologies working at Vitra Bioscience, following my undergraduate degree. Driven to help address cancer and other complex diseases at a more direct and personal level, I earned my Doctor of Medicine degree from the University of Miami, followed by a Masters in Public Health. After an internship in surgery at Harvard, I completed postgraduate Radiology training at UC Davis and further subspecialized in Nuclear Medicine training at Stanford University, where I learned about neuroendocrine tumors having witnessed NETTER-1 trial participants. I had the privilege of joining a large integrated healthcare provider in Northern California where I worked to enable NET patients’ early access to 177Lu-Dotatate(Lutathera, prior to FDA approval. Subsequently I became the Nuclear Medicine physician lead for regional multidisciplinary NET tumor boards facilitating patient cases to be rigorously reviewed with an integrated, patient-centered focus. Currently, as an Associate Professor at the University of Arizona, my focus is on advancing NET patient care and research, while teaching and inspiring the next generation of Nuclear Radiologist/Oncologist. It is an honor to be invited to participate in the LACNETS outreach program. Dr. Gregory Woodhead Interventional Radiology, University of Arizona Cancer Center (UACC) Gregory Woodhead, MD, PhD, joined the interventional radiology faculty at University of Arizona, with the majority of his practice focusing on interventional oncology at the University of Arizona Cancer Center. Dr. Woodhead’s career objective is to translate devices and therapies from the development stage into clinical practice. His interest in cancer cell biology draws from his PhD research on the role of the catenin-signaling pathway in cell fate decisions for progenitor and cancer cells. As a resident and fellow at the University of Arizona, he embarked on an analysis of catheter-directed mechanical thrombectomy for the treatment of acute pulmonary embolism (PE), which is a common cause of morbidity and mortality in cancer patients. He is the PI on multiple trials and registries that seek to identify long-term differences in patients who received mechanical thrombectomy for PE in comparison to those who received only anticoagulation alone. Dr. Woodhead has published over 40 papers and frequently presents at national and international meetings. He is an integral member of multiple institutional programs and a committee member for many professional societies. He is passionate about educating and mentoring medical students, residents, and fellows. He previously served as the chair of the MD/PhD admission committee.

<< Go back to the Podcast page EPISODE 38: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES PART I: Overview and Ablative Techniques Including Histotripsy Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. MEET DR. OSMAN AHMED Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY INCLUDING HISTOTRIPSY: What is liver-directed therapy? How does it work? Is this considered “surgery”? What is a surgery and what is a “procedure?” What are the types of liver-directed therapies used for neuroendocrine cancer? Which neuroendocrine cancers are they used for and when are they used? How do you decide who is a good candidate and if it will be effective? When are liver-directed therapies NOT used? Can someone who has had a Whipple undergo liver-directed therapy? What is the ablation zone? What is a heat sink effect? What is histotripsy? How does it work? When is histotripsy used (tumor grade, type of tumor - PNET/lung NET, size, number of tumor, location)? Can they be used for liver tumors even if there are tumors outside the liver? What are the limitations to histotripsy? What happens to the liver tissue after ablation? What are the results or success rates of patients being treated? Can histotripsy “cure” NET? How do you decide between the various types of liver-directed therapies? RESOURCES WATCH LACNETS Liver-Directed Therapy Videos READ "First Release #HOPE4LIVER Data Reveals 'Exciting' Potential of Histotripsy for Liver Tumours" "The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors" "HistoSonics® Publishes Results of its Pivotal #HOPE4LIVER Trials" OTHER RESOURCES The company, HistoSonics recently launched a new website – called myhistotripsy.com – to help educate patients on histotripsy and help them locate treatment sites. The website offers an overview of histotripsy and features patient stories, a form to help determine if histotripsy is right for you, and resources to find a doctor near you. Visit the Patient Website DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

< Back to the upcoming events page Learn about Tyrosine Kinase Inhibitors (TKIs), what they are and how they work, with NET expert Dr. Jennifer Chan. Dr. Chan is the Vice President of the North American Neuroendocrine Tumor Society (NANETS) and the principal investigator of the CABINET trial. Hear the positive findings from that TKI study using Cabozantinib. She discusses the latest in TKI treatments and how they may be a possible treatment option for many NET patients. ABOUT DR. JENNIFER CHAN Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. She focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. Dr. Chan is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. She has been the principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and has been involved in studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors. Dr. Chan is a past chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS) and the current Vice President of NANETS. She serves on the National Comprehensive Center Network (NCCN) Neuroendocrine Tumors Guidelines Panel. Dr. Chan is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute and the Board of Directors of NANETS. SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

<< Go back to the Podcast page EPISODE 50 - Spotlight on Pharmacists Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is a pharmacist, and how are they involved in the care of neuroendocrine cancer patients? In this episode, Dr. Amanda Cass, a clinical pharmacist in the Thoracic Oncology Clinic at Vanderbilt Medical Center, explains the unique role pharmacists play—why they’re sometimes called “doctor,” how they support patients starting treatments such as cabozantinib and CAPTEM, and practical tips for staying organized, managing side effects, and navigating medication costs. MEET AMANDA CASS Dr. Cass is a clinical pharmacist in the Thoracic Oncology Clinic at Vanderbilt University Medical Center. She received her Doctorate of Pharmacy from the University of Kentucky College of Pharmacy in 2016 and subsequently completed her Pharmacy Practice Residency at Grady Health System and became a Board Certified Pharmacotherapy Specialist in 2017. In 2018, she completed her Oncology Pharmacy Residency at the University of North Carolina Medical Center. Dr. Cass's previous research interests included opioid use in non-metastatic cancer patients after curative treatment and albumin effects on oxaliplatin related toxicities. Her current areas of interest are molecular mutations and use of targeted therapies in NSCLC, immunotherapy in SCLC, and global oncology care. Dr. Cass is the preceptor for the Outpatient Thoracic Oncology Rotation. TOP TEN QUESTIONS: Getting to Know the Pharmacist 1. What exactly does a pharmacist do, and what training do they go through? 2. Why are pharmacists sometimes called “doctor,” and how is that different from a physician? 3. What role does a pharmacist play on the cancer care team? 4. How are pharmacists involved in caring for neuroendocrine cancer patients, both directly and behind the scenes? How Pharmacists Support Treatment 5. How can a pharmacist help when someone is starting a new treatment for neuroendocrine cancer? Walk us through an example with Cabozantinib: how do you guide patients in understanding it, taking it, and managing side effects? 6. Walk us through another example with CAPTEM (capecitabine and temozolomide): how do you guide patients in understanding it, taking it, and managing side effects? Practical Tips for Patients 7. What are some simple ways to stay organized, like keeping a medication list or symptom journal? 8. What practical tips do you share with patients about tracking and managing side effects at home? Access and Communication 9. Who can patients talk to about medication costs or financial assistance? 10. How does someone find a pharmacist to talk to, and is it important to find one with neuroendocrine cancer experience? RESOURCES EXPLORE Cabometyx Patient Care Kit: www.cabometyx.com/resources Questions to Ask Your Pharmacists Medication reminder apps: Medisafe Dosecast - link for Apple & for iOS EveryDose MedMinder - link for Apple and for iOS Pillo - A.K.A. The Angry Pill Box MyTherapy DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 21: WHAT TO KNOW ABOUT SMALL BOWEL NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutchinson Cancer Center in Seattle answers 10 common questions about small bowel NETs. MEET DR. DAVID B. ZHEN Dr. David Zhen is a medical oncologist who specializes in treating patients with gastrointestinal cancers. His research centers around the development of clinical trials evaluating new therapies and combination approaches for the treatment of patients with gastrointestinal cancers, particularly for neuroendocrine and gastroesophageal cancers. He is also conducting research to understand the interactions of the immune system in gastrointestinal cancers and how this can be manipulated to improve upon the response to immunotherapy drugs called checkpoint inhibitors, which block a braking system that cancers use to tamp down the immune response. TOP 10 QUESTIONS 1. What are small bowel NETs? Where are they located? 2. How are small bowel NETs found? What are the symptoms of a small bowel NET? 3. What types of labs, scans, or testing is done to determine if someone has a small bowel NET? Why are small bowel NETs not found in routine endoscopy or colonoscopy? 4. What are some ways that small bowel NETs differ from other types of NETs? What makes small bowel NETs unique from other types of NETs? 5. How do you decide if the small bowel NET(s) can be surgically removed? What type of surgeon would make that determination? 6. How are small bowel NETs treated medically? 7. How are treatments sequenced? 8. How are the treatments different from other NETs? 9. What are some exciting new treatments in the pipeline for small bowel NETs? What are clinical trials we should be aware of for small bowel NETs? 10. How are small bowel NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for small bowel NETs? Bonus: What words of hope would you like to share with the NET community? RESOURCES WATCH "Systemic Therapy: GI NET" - 2020 LACNETS Patient Education Conference Recording of Dr. Zhen Visiting the LACNETS Support Group Patient Story: From Diagnosis to Patient Advocacy - 2022 LACNETS NET Patient Conference NET Patient shares how she has learned not just to survive, but also to thrive . LISTEN Listen to the NETRF NETWise Special Episode: Small Bowel NET + Take the LACNETS Quiz READ 2017 The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society 2017 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

< Back to the upcoming events page Download PowerPoint Slides >>> Some Topics Covered: Types of Functional Neuroendocrine Tumors, Hormone-producing, Carcinoid Syndrome, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Diarrhea, Flushing, Hypoglycemia, Carcinoid Heart Disease, Cushing Syndrome, Somatostatinoma. ABOUT Join us for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), carcinoid syndrome (excess serotonin), and other hormone-related issues and symptoms. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. THANKS TO OUR SPONSORS PRESENTING SPONSOR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

NET RETREAT: Retreatment with 177Lu-DOTATATE vs Everolimus in Metastatic Midgut NET << Back NET RETREAT: Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT05773274 DRUG/TREATMENT: Lu-177 Dotatate PRRT or Everolimus PHASE: 2 STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) Dr. Aman Chauhan Discusses NET Retreat DESCRIPTION: This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to treatment with everolimus in patients with midgut neuroendocrine tumors that have spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT involves treatment with a radioactive substance that is linked to a peptide receptor so that it will attach to a specific cell type when injected into the body. 177Lu-DOTATATE, a PRRT drug, may increase the length of time until worsening of disease by 8 months compared to the usual approach. Everolimus treats cancer by stopping cancer cells from reproducing and by decreasing blood supply to the cancer cells. Everolimus prevents transplant rejection by decreasing the activity of the immune system. Giving 177Lu-DOTATATE may work better in shrinking and stabilizing tumors in patients with neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigators: Dr. Simron Singh, Canadian Cancer Trials Group Dr. Aman Chauhan, SWOG Cancer Research Network

IL13Rα2 CAR T Cell Study for Solid Tumor Cancers << Back Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT04119024 DRUG/TREATMENT : IL13Ralpha2 CAR T Cells PHASE : 1 STATUS : Recruiting at Stanford Medicine, UCLA, and City of Hope SPONSOR : CIRM DESCRIPTION: Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024 This clinical trial investigates a novel gene therapy (IL13Ralpha2 CAR T cells) approach for advanced melanoma and other solid tumors. It aims to assess the safety and effectiveness of gene-modified immune cells targeting cancer cells. The trial seeks to determine the safety and potential effectiveness of IL13Ralpha2 CAR T cells in fighting cancer. By evaluating the dose and the IL13Ralpha2 CAR T cells ability to attack cancer cells, researchers at UCLA, Stanford, and City of Hope aim to improve treatment options for advanced cancers. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Christy Sidhu; UCLA = Jonsson Comprehensive Cancer Center EMAIL: PICICenterResearch@mednet.ucla.edu PHONE: 310-206-5087 Principal Investigators: Dr. Antoni Ribas, MD, PhD (UCLA) Dr. Allison Betof Warner, MD, PhD (Stanford Medicine) Dr. Yan Xing, MD, PhD (City of Hope) RESOURCES : Patient Information Sheet

Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC << Back Ph I/II Trial of Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC CLINICALTRIALS.GOV IDENTIFIER: NCT03647163 Drug/Treatment: VSV-IFNβ-NIS and Pembrolizumab PHASE: I/II STATUS: Recruiting Sponsor: Vyriad, Inc. Collaborator: Mayo Clinic Dr. Heloisa Soares Discusses Systemic VSV-IFNβ-NIS and Pembrolizumab DESCRIPTION: Vyriad is sponsoring the safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion of the trial will be used for the expansion portion. The study has been conducted with a dose of 1.7 × 1010 as the recommended phase II dose in an expansion cohort of 10 patients with NSCLC. However, current data suggests that VSV-IFNβ-NIS doses of up to 1.7 × 1011 is safe and likely more efficacious. Thus, this study will test a second VSV-IFNβ-NIS dose level, 1.0x1011 TCID50. A safety assessment will be carried out after 3 patients are enrolled. If this dose schedule is well tolerated and virus PK are not negatively impacted, both the NSCLC and NEC expansion cohorts will open using this dose schedule. If 2 of the first 3 patients or 2 of the first 6 patients experience a DLT, the dose will be de-escalated to 5 x 1010. The safety run-in/dose escalation portion of this study is expected to require a minimum of 3 patients and a maximum of 18 patients (6 patients per dose level). The expansion portion of this study is expected to require a minimum of 10 per cohort. The NSCLC and NEC patients enrolled at the identified optimal dose in the dose escalation cohort would be included in the dose expansion cohort if they are evaluable for the primary endpoint in the expansion portion (4 dose escalation patients at the optimal dose are expected to roll over to the expansion). Therefore, the overall sample size details will be a maximum of 40 patients. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Jennifer Boughton EMAIL: JBoughton@vyriad.com PHONE: 908-553-3135 Shruthi Naik, PhD EMAIL: snaik@vyriad.com PRINCIPAL INVESTIGATOR: Julian R. Molina, MD, PhD Mayo Clinic

<< Go back to the Podcast page EPISODE 36: NEN TREATMENTS: FOCUS ON IMMUNOTHERAPY Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs. MEET DR. JENNIFER EADS Dr. Jennifer Eads is an associate professor of medicine at the University of Pennsylvania, Abramson Cancer Center where she is a gastrointestinal medical oncologist focusing on the treatment of and research in patients with neuroendocrine tumors and gastroesophageal cancers. She is the Physician Lead for GI Clinical Research, overseeing the Penn GI clinical research portfolio. She is the Penn institutional principal investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN) and serves as the Director of the National Clinical Trials Network (NCTN) for the Abramson Cancer Center. She has served as principal investigator for multiple phase I/II/III clinical trials, including as the national study chair for multiple cooperative group trials. She has served on the National Clinical Cancer Network (NCCN) neuroendocrine tumors guidelines committee, is a former member of the North American Neuroendocrine Tumor Society (NANETS) Board of Directors and is currently on the Board of Scientific Advisors for the Neuroendocrine Tumor Research Foundation (NETRF). In 2022, she was named as the ECOG-ACRIN Young Investigator of the Year. TOP TEN QUESTIONS ABOUT NEN TREATMENTS: What is immunotherapy? How does it work? How does immunotherapy differ from other treatments? When is immunotherapy used? Which neuroendocrine cancers are they used for? What are the various immunotherapy drugs used for neuroendocrine cancer and how do they work? What are immune checkpoint inhibitors? What is CAR-T therapy? What is DLL3? What is vaccine therapy? What side effects might someone have when taking immunotherapy? How does it make me look (will I lose my hair)? How will it make me feel (will I be able to work)? Does immunotherapy cause someone to be immunocompromised? What monitoring needs to be done while on immunotherapy? How do you decide when to use immunotherapy, which to use, and for what patient? What do you see as the future of immunotherapy in neuroendocrine cancer treatment? RESOURCES Immunotherapy Trials for NENs Clinical trials mentioned in this episode: CHM-2101 CAR-T cell for GI Cancers DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum WATCH DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 48 - NEN TREATMENTS: FOCUS ON DLL3 Download a Transcript of this Episode >>> ABOUT THIS EPISODE DLL3 is emerging as a promising new target for neuroendocrine cancers. In this episode, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explains what DLL3 is, how it works, who might benefit, and what current clinical trials are teaching us. He breaks down the science, treatment options, and future directions in a way that is clear, approachable, and designed to help patients and families better understand this developing area of care. MEET DR. ROHIT THUMMALAPALLI Rohit Thummalapalli is a gastrointestinal medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center specializing in clinical care and research in patients with neuroendocrine and biliary tract cancers. Originally from Florida, Dr. Thummalapalli completed medical training at Harvard and Johns Hopkins before arriving at MSK as a medical oncology fellow in 2021, and started on faculty in 2024. TOP TEN QUESTIONS: Understanding the Basics What is immunotherapy? How does immunotherapy work? What is DLL3? How does it work in the context of neuroendocrine cancer? How is DLL-targeted therapy similar to or different from other types of immunotherapy? Is there evidence that one works better than another? Indications, Use, Access & Availability When is DLL3 used in neuroendocrine cancers? What types of neuroendocrine cancer might express DLL3? How does someone know if this is a potential treatment option for them? c. At what point in a patient’s treatment journey might DLL3 be considered? d. How and where DLL3 is available for neuroendocrine cancer patients? What are other ways, if any, to access DLL3? Testing for DLL3 Expression How does someone find out if their tumors express DLL3 receptors? How & where is DLL3 expression tested? It it tested through tissue samples, imaging, or something else? Is there a minimal level of DLL3 expression that is required to receive the treatment? (Does the threshold vary by trial?) Does the level of DLL3 expression differ by institution? Does the level of DLL3 expression predict how well someone might respond to treatment? Can the tumor expression of DLL3 vary from tumor to tumor? Can it vary over time, meaning can tumors gain or lose expression? Do you measure the DLL3 expression following treatment? Treatment Considerations How effective is DLL3-targeted therapy in neuroendocrine cancers? What is the goal of treatment with DLL3 – shrinkage, stabilization, symptom relief? How long is it expected to work? How do you measure the response to DLL3 treatment? Can DLL3 be combined with other therapies? Decision-Making and Patient Counseling How do you decide when to offer DLL3 for someone with neuroendocrine cancer? What factors or prior treatments might make someone ineligible for DLL3 therapy? Could receiving DLL3 exclude a patient from other treatments or clinical trials? How do you counsel patients who are considering DLL3? What should they know about how the treatment is given, possible side effects, and what’s known (or unknown) about long-term safety? What should one expect in terms of frequency of visits, hospitalization and side effects? Can someone still work while receiving DLL3? Looking Ahead What are the key questions you hope to answer about DLL3 in the next year? What do you hope to learn over the next 3 to 5 years? RESOURCES LISTEN Neuroendocrine Cancer Foundation Podcast Episode 36: NEN Treatments: Focus on Immunotherapy EXPLORE Clinical Trials Guide: Immunotherapy READ Landscape of functional DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) (May 28, 2025) Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial (May 28, 2025) Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms - JCO Precision Oncology, November 20, 2025 WATCH Dr. Strosberg on Research Clarifying the Role of Obrixtamig in SCLC and Other Neuroendocrine Cancers (May 5, 2025) Obrixtamig Could Broaden the Reach of DLL3/CD3-Targeted BiTEs in Small Cell Lung and Other Neuroendocrine Cancers (May 5, 2025) IMMUNOTHERAPY-BASED DLL3-TARGETED CLINICAL TRIALS Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms NOVEL NON-IMMUNOTHERAPY-BASED DLL3-TARGETED CLINICAL TRIALS Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56, a DLL3-targeting Monoclonal Antibody A Study of ZL-1310 in Participants With Selected Solid Tumors 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

SORENTO™: Subcutaneous Octreotide for GEP-NETs (CAM2029) << Back SORENTO ™ - A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETs CLINICALTRIALS.GOV IDENTIFIER: NCT05050942 DRUG/TREATMENT: CAM2029, octreotide LAR, lanreotide ATG PHASE: 3 STATUS: Recruiting SPONSOR: Camurus AB Dr. Simron Singh Discusses the SORENTO™ Trial DESCRIPTION: Camurus is sponsoring a phase 3 study to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Camurus AB EMAIL: medicalinfo@camurus.com PHONE: +46 46 286 57 30 Principal Investigator: Simron Singh, MD, MPH Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada